<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Etiology and pathophysiology of polycystic ovary syndrome in adolescents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Etiology and pathophysiology of polycystic ovary syndrome in adolescents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Etiology and pathophysiology of polycystic ovary syndrome in adolescents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Natalie Shaw, MD, MMSc
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert L Rosenfield, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mitchell E Geffner, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diane Blake, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 11, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polycystic ovary syndrome (PCOS) accounts for the vast majority of anovulatory symptoms and hyperandrogenism in women [
         <a href="#rid1">
          1
         </a>
         ]. The diagnosis of PCOS has lifelong implications, with increased risk for infertility, metabolic syndrome, type 2 diabetes mellitus, cardiovascular disease, and endometrial carcinoma [
         <a href="#rid2">
          2-6
         </a>
         ]. Mendelian randomization studies have suggested that PCOS in and of itself directly causes some (eg, estrogen receptor-positive breast cancer), rather than all (eg, type 2 diabetes, cardiovascular events), of these conditions [
         <a href="#rid7">
          7
         </a>
         ]. Type 2 diabetes, for example, seems in part to be causally related to a family history of diabetes and the insulin resistance and/or obesity that are frequent comorbidities among women with PCOS [
         <a href="#rid7">
          7-9
         </a>
         ]. Endometrial carcinoma is more closely related to obesity and hormonal traits than to genetic PCOS risk factors [
         <a href="#rid4">
          4-6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5852.html" rel="external">
          "Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         This presentation of the etiology and pathophysiology of PCOS provides the rationale for the diagnosis and management of PCOS in adolescents, which are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5852.html" rel="external">
          "Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/94182.html" rel="external">
          "Diagnostic evaluation of polycystic ovary syndrome in adolescents"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5853.html" rel="external">
          "Treatment of polycystic ovary syndrome in adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2015727218">
         <span class="h1">
          ETIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         PCOS is considered to be a complex trait arising from the interaction of genetic and environmental factors, usually first presenting when mature gonadotropin levels are achieved at puberty [
         <a href="#rid1">
          1
         </a>
         ]. It occurs naturally in nonhuman primates as well as humans [
         <a href="#rid10">
          10
         </a>
         ]. The pathogenesis of PCOS can be envisioned according to a "two-hit" hypothesis, whereby the disorder arises as a congenitally programmed predisposition ("first hit") that becomes manifest in the presence of a provocative factor ("second hit")  (
         <a class="graphic graphic_table graphicRef111333" href="/z/d/graphic/111333.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. The congenital factors can be either hereditary (genetic) or acquired (eg, maternal androgens or nutritional disorders affecting the fetus). The postnatal provocative factor usually is insulin resistance, with compensatory hyperinsulinism, which may have been congenitally programmed and/or acquired postnatally due to simple (exogenous) obesity. (See
         <a class="local">
          'Insulin-resistant hyperinsulinism'
         </a>
         below.)
        </p>
        <p>
         These complex interactions generally mimic an autosomal dominant pattern of inheritance with variable penetrance. Heritability of PCOS has been estimated at over 70 percent, based on studies in identical twin sisters [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         PCOS represents an evolutionary paradox: Although it is an infertility disorder, it is very common across populations [
         <a href="#rid1">
          1
         </a>
         ]. One reasonable explanation for this paradox is that PCOS developed through natural selection because it was advantageous during times of nutritional deprivation, since the condition helps to preserve anabolism and reproductive capacity via increased androgen and insulin production and fat storage [
         <a href="#rid12">
          12,13
         </a>
         ]. By contrast, in current times of plentiful nutrition and obesity, this phenotype is disadvantageous. One of the great mysteries about the etiology of PCOS is the nature of the common denominator that underlies ovarian hyperandrogenism, insulin resistance, and obesity. Considerable basic research will be necessary to discern this. Understanding of the pathophysiology is summarized in the following sections [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3142989519">
         <span class="h2">
          Heritable traits
         </span>
         <span class="headingEndMark">
          —
         </span>
         Heritable traits that are PCOS risk factors include maternal PCOS, polycystic ovary morphology (PCOM), hyperandrogenemia, and metabolic syndrome.
        </p>
        <p class="headingAnchor" id="H536635003">
         <span class="h3">
          Maternal polycystic ovary syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maternal PCOS is a risk factor for PCOS in daughters; approximately 25 percent of females with PCOS have a mother with PCOS, although estimates vary widely [
         <a href="#rid14">
          14-16
         </a>
         ]. The largest long-term prospective study compared the daughters of 99 women with PCOS (defined by National Institutes of Health [NIH] criteria) with those of 88 control women [
         <a href="#rid17">
          17,18
         </a>
         ]. Higher dehydroepiandrosterone sulfate (DHEAS) levels emerged peripubertally, and higher basal testosterone and 17-hydroxyprogesterone (17OHP) responses to gonadotropin-releasing hormone agonist (GnRHa) testing emerged during the late stages of puberty. One-half of the daughters of women with PCOS who were postmenarchal had higher testosterone levels than any daughters in a control group. Twenty-one of these daughters were reported in 2019 to have reached 18 to 21 years of age: 11 met NIH criteria for PCOS (Rotterdam phenotypes A-B) and five had ovulatory PCOS (Rotterdam phenotype C) [
         <a href="#rid19">
          19
         </a>
         ]. This represented a fivefold increased risk of developing PCOS compared with daughters of non-PCOS controls.
        </p>
        <p class="headingAnchor" id="H2599052188">
         <span class="h3">
          Polycystic ovary morphology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polycystic ovary morphology (PCOM) refers to the ultrasonographic polycystic changes in the ovary that are variably associated with PCOS (see
         <a class="medical medical_review" href="/z/d/html/94182.html" rel="external">
          "Diagnostic evaluation of polycystic ovary syndrome in adolescents", section on 'Ultrasonography'
         </a>
         ). This characteristic seems to be inherited in an autosomal dominant fashion in PCOS [
         <a href="#rid20">
          20,21
         </a>
         ]. In our study of 35 families with an adolescent PCOS proband (by NIH criteria), most adolescents had either a mother with PCOM (22 percent), usually without PCOS symptoms, or a parent with metabolic syndrome [
         <a href="#rid14">
          14
         </a>
         ] (see
         <a class="local">
          'Metabolic syndrome'
         </a>
         below). In a study of the sisters of women with PCOM who met the broad Rotterdam criteria for PCOS (80 percent of whom were clinically hyperandrogenic), 70.5 percent of sisters had PCOM [
         <a href="#rid22">
          22
         </a>
         ]. Among the sisters with PCOM, 25 percent had hyperandrogenic anovulation (ie, PCOS by the highly specific NIH criteria) (see
         <a class="medical medical_review" href="/z/d/html/5852.html" rel="external">
          "Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents"
         </a>
         ), 42 percent had either hirsutism or oligomenorrhea (ie, meeting less specific criteria for PCOS), and 33 percent were asymptomatic. The group of sisters with PCOM resembled their proband sisters in both androgenic and glucose-metabolic traits, indicating significant heritability and cosegregation of these traits.
        </p>
        <p>
         These and other genetic studies do not include data on the steroidogenic function of a polycystic ovary, which varies substantially among individuals with PCOM. Approximately one-half of apparently normal females with PCOM have subclinical biochemical evidence of ovarian androgenic dysfunction, which has been proposed to represent a carrier state for PCOS [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H692268526">
         <span class="h3">
          Hyperandrogenemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum testosterone and sex hormone-binding globulin levels are heritable in women [
         <a href="#rid23">
          23
         </a>
         ]. Approximately one-half of sisters of PCOS probands have an elevated serum testosterone level [
         <a href="#rid24">
          24
         </a>
         ]. However, only one-half of these sisters with excess androgen have menstrual irregularity and the other one-half are asymptomatic. This is consistent with the concept that a modest degree of hyperandrogenemia is not sufficient to account for ovarian dysfunction in the absence of another predisposing or precipitating factor(s).
        </p>
        <p>
         First-degree male relatives of women with PCOS have variably been reported to have subtle excesses of adrenal steroids and serum luteinizing hormone (LH) [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H451685201">
         <span class="h3">
          Metabolic syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Metabolic syndrome (a cluster of central obesity, hyperglycemia, dyslipidemia, and hypertension) and its core pathogenetic constituents, insulin resistance and obesity, have heritable components [
         <a href="#rid1">
          1
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">
          "Metabolic syndrome (insulin resistance syndrome or syndrome X)"
         </a>
         ). Defective insulin secretion is also highly heritable in PCOS and is closely associated with the most common subtype of PCOS [
         <a href="#rid1">
          1,27
         </a>
         ]. (See
         <a class="local">
          'Primary functional ovarian hyperandrogenism'
         </a>
         below.)
        </p>
        <p>
         There is a high prevalence of metabolic syndrome or its components (eg, insulin resistance and/or obesity) in first-degree relatives of PCOS patients, suggesting that these factors are strongly associated with the pathogenesis of PCOS [
         <a href="#rid1">
          1,26
         </a>
         ]. This was illustrated in our series of 35 families in which an adolescent girl had PCOS (by NIH criteria): 70 percent of the probands had a parent with metabolic syndrome (53 to 79 percent of fathers and 34 to 37 percent of mothers were affected, depending on the criteria used) [
         <a href="#rid14">
          14
         </a>
         ]. Obesity or overweight was found in 94 percent of fathers and 66 percent of mothers. Abnormal glucose tolerance was present in 84 percent of fathers and 49 percent of mothers; most of these were asymptomatic. Genes identified by genome-wide association studies (GWAS) as associated with PCOS were also found to be associated with obesity, type 2 diabetes, and androgenetic alopecia in men [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="local">
          'Genetic variation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1972857802">
         <span class="h3">
          Genetic variation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ongoing research aims to identify specific genes that underlie PCOS pathophysiology. A wide variety of genetic variants with linkage to and/or association with PCOS have been identified by candidate gene and molecular genetic studies [
         <a href="#rid1">
          1
         </a>
         ], and novel loci are reported regularly [
         <a href="#rid28">
          28-32
         </a>
         ]. Many of these genes encode proteins with plausible roles in PCOS pathophysiology (eg, steroidogenic enzymes, sex hormone-binding globulin, androgen receptor, transcription factors, and gonadotropins and their receptors) or proteins related to insulin sensitivity and obesity.
        </p>
        <p>
         The candidate gene approach led to the discovery of coding and regulatory variants in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F600957&amp;token=87jLzclRwWxNoI%2BQq5Gg7zel46y5KQ5SnFBl9ZfSUMEwmfPAy2vDIMEOJYJQDfEq&amp;TOPIC_ID=5799" target="_blank">
          <i>
           AMH
          </i>
         </a>
         (anti-müllerian hormone) and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F600956&amp;token=87jLzclRwWxNoI%2BQq5Gg70IlXEWhYYiat0vbPEOy%2B0NY%2BwPp9tyN4AXsMsh6zGhj&amp;TOPIC_ID=5799" target="_blank">
          <i>
           AMHR
          </i>
         </a>
         (AMH receptor) genes in 6.7 percent of PCOS patients [
         <a href="#rid33">
          33
         </a>
         ]. In silico and in vitro studies suggest that these variants cause decreased signaling and may have pathogenic significance.
        </p>
        <p>
         PCOS prevalence seems to be increased in McCune-Albright syndrome, an uncommon disorder caused by a constitutively activated or gain-of-function mutation in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F139320&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2FJVMQV2IOHvslvqeTswVWsmYQCh288JmF62eAi4vcP%2F&amp;TOPIC_ID=5799" target="_blank">
          <i>
           GNAS1
          </i>
         </a>
         [
         <a href="#rid34">
          34
         </a>
         ]. Linkages for polymorphisms in diverse signaling pathway genes have been robust in many populations [
         <a href="#rid1">
          1
         </a>
         ]. Dysregulation of genes involved in cell growth or division is suggested by reports of upregulation of proto-oncogenic genes in endometrium and of telomere shortening in leukocytes of women with PCOS [
         <a href="#rid1">
          1
         </a>
         ]. In most instances, it remains unclear how these genetic variants might interact to induce the core abnormalities of PCOS. (See
         <a class="medical medical_review" href="/z/d/html/7430.html" rel="external">
          "Epidemiology, phenotype, and genetics of the polycystic ovary syndrome in adults", section on 'Current perspective'
         </a>
         .)
        </p>
        <p>
         Several important investigations utilized GWAS to identify genes linked to PCOS, commencing with a series of studies conducted in large populations of ethnic Han Chinese in 2011 [
         <a href="#rid1">
          1
         </a>
         ]. The major findings in this population have been generally replicated in most other populations studied. A meta-analysis of GWAS studies identified 13 loci common to all PCOS diagnostic criteria that were also associated with hyperandrogenism, gonadotropin levels, and testosterone levels, as well as the metabolic traits associated with PCOS [
         <a href="#rid35">
          35
         </a>
         ]. Mendelian randomization analyses suggested that a shared genetic architecture contributes to PCOS, body mass index, fasting insulin, menopause timing, depression, and male-pattern balding. The molecular mechanisms by which most of the candidate genes plausibly contribute to PCOS are not clearly understood [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         One of the most striking findings from GWAS studies in diverse PCOS cohorts has been the discovery of the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F613633&amp;token=87jLzclRwWxNoI%2BQq5Gg7zqtDnkbfBsxX6wFr3KfmbfS19qIDzp%2BeC15AgeaPh4l&amp;TOPIC_ID=5799" target="_blank">
          <i>
           DENND1A
          </i>
         </a>
         (differentially expressed in normal and neoplastic development isoform 1A) locus [
         <a href="#rid1">
          1,37-39
         </a>
         ]. The truncated splice variant of
         <em>
          DENND1A
         </em>
         , termed
         <em>
          DENND1A.V2
         </em>
         , encodes a previously unrecognized protein.
         <em>
          DENND1A.V2
         </em>
         is normally found in theca and in zona reticularis cells and is significantly overexpressed in PCOS theca cells, where it accounts for the PCOS biochemical phenotype in cultured theca cells [
         <a href="#rid1">
          1,40
         </a>
         ]. In addition, in transgenic mice, overexpression of human
         <em>
          DENNDIA.V2
         </em>
         drives both adrenal and ovarian steroidogenesis [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         A whole-genome sequencing study of 261 individuals from 62 PCOS families also implicated rare (minor allele frequency ≤2 percent) noncoding variants at the
         <em>
          DENND1A
         </em>
         locus in a number of PCOS-related reproductive and metabolic phenotypes [
         <a href="#rid42">
          42
         </a>
         ]. One-half of these PCOS families had one or more of 30 rare
         <em>
          DENND1A
         </em>
         variants. The vast majority of these were noncoding variants, most of which were predicted to alter V2 expression via altered binding of transcription factors or RNA-binding proteins; it was proposed that these variants regulate key biologic pathways of
         <em>
          DENND1A
         </em>
         action. (See
         <a class="medical medical_review" href="/z/d/html/7430.html" rel="external">
          "Epidemiology, phenotype, and genetics of the polycystic ovary syndrome in adults", section on 'Genetics'
         </a>
         .)
        </p>
        <p>
         Cluster analysis based on anthropometric, reproductive, and metabolic traits in a population of nearly 1000 women of European descent with hyperandrogenic oligo-amenorrhea showed two distinct clusters of cases: a relatively nonobese group (21 to 23 percent of cases) with higher LH and higher sex hormone-binding globulin levels (termed "reproductive" group) and a relatively obese group (37 to 39 percent) with higher glucose and insulin levels ("metabolic" group) [
         <a href="#rid43">
          43
         </a>
         ]. Applying this conceptual framework to a family-based cohort of 73 women with PCOS with genotypic data, the investigators found that
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F613633&amp;token=87jLzclRwWxNoI%2BQq5Gg7zqtDnkbfBsxX6wFr3KfmbfS19qIDzp%2BeC15AgeaPh4l&amp;TOPIC_ID=5799" target="_blank">
          <i>
           DENND1A
          </i>
         </a>
         <em>
         </em>
         variants were significantly more frequent in the reproductive phenotype group. These findings suggest that different genetic and biologic pathways are involved in the pathogenesis of these PCOS subtypes.
        </p>
        <p>
         Several micro-RNAs have been incriminated in PCOS steroidogenesis and/or folliculogenesis [
         <a href="#rid44">
          44-46
         </a>
         ]. These molecules inhibit gene expression via one or more post-transcriptional mechanisms. Theca cell profiling of micro-RNAs identified miR-130b-3p as one differentially expressed between women with PCOS and controls [
         <a href="#rid36">
          36
         </a>
         ]. Expression of this micro-RNA was decreased in PCOS theca cells inversely to both
         <em>
          DENND1A.V2
         </em>
         expression and androgen biosynthesis. Pathway and network analysis suggested that miR-130b-3p was at the hub of a network that involves
         <em>
          DENND1A.V2
         </em>
         and two other GWAS candidate genes,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F179514&amp;token=tEpDslnpc0F0kICl%2Fz7sFeJEtfajUCPcRjYRwn%2FUxWCTWdF7SIGKGqGycrXjk0ZN&amp;TOPIC_ID=5799" target="_blank">
          <i>
           RAB5B
          </i>
         </a>
         (Ras-related protein 5B, which encodes a GTPase involved in vesicular transport from the plasma membrane) and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F152790&amp;token=tEpDslnpc0F0kICl%2Fz7sFdq7KW313yBvat27CnEqDw%2Fgu0gA9BASBlnD2WO8d765&amp;TOPIC_ID=5799" target="_blank">
          <i>
           LHCGR
          </i>
         </a>
         , the gene encoding the LH receptor. miR-130b-3p also links this network to the insulin mitogenic signaling pathway. Thus, it was postulated that decreased miR-130b-3p may mediate the increased theca cell hyperandrogenism of PCOS by post-transcriptional upregulation of LH receptor signaling via this gene network [
         <a href="#rid36">
          36
         </a>
         ].
         <em>
          DENND1A.V2
         </em>
         also may directly stimulate steroidogenic transcription [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Many genes identified by GWAS have no obvious reproductive or metabolic relevance. This has led to the utilization of diverse pathway analyses to understand gene action. These approaches are in their infancy. Ten micro-RNAs have been identified that are associated with PCOS or obesity and indicate specific signaling pathway alterations in these conditions [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3623010734">
         <span class="h3">
          Epigenetic changes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epigenetic changes are increasingly suspected to be important to the pathogenesis of PCOS. Abnormal epigenetic methylation of cytosine-guanine (CpG) islands have been identified in tissues from adult women with PCOS. These alter gene expression and may reflect environmental exposures [
         <a href="#rid49">
          49
         </a>
         ]. Methylation differences at the androgen receptor (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F313700&amp;token=87jLzclRwWxNoI%2BQq5Gg78HIssFNrm%2Bal0aWQkL0TQf05RpCFMZUdPJrO5oOE6y1&amp;TOPIC_ID=5799" target="_blank">
          AR
         </a>
         ) intron-exon boundaries were observed that were postulated to promote AR alternative splicing in PCOS granulosa cells [
         <a href="#rid50">
          50
         </a>
         ]. Two novel splice variants of the AR were discovered in these cells that altered both AR recruitment to deoxyribonucleic acid (DNA) and androgen-mediated changes in the expression of genes affecting steroidogenesis and folliculogenesis [
         <a href="#rid50">
          50
         </a>
         ]. Another study showed deleterious AR mutations in 3 of 258 Han Chinese patients [
         <a href="#rid51">
          51
         </a>
         ]. Abnormal DNA methylation has been observed in multiple PCOS tissues [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2196111683">
         <span class="h2">
          Intrauterine environment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Insults to the intrauterine environment induce persistent changes in the developing embryonic and fetal epigenome that lead to altered gene expression and disease in later life [
         <a href="#rid1">
          1
         </a>
         ]. In a small study comparing PCOS progeny with non-PCOS progeny (24 sons and daughters in each group), sex-specific differences were identified in DNA methylation levels in promoter regions of the genes encoding the androgen receptor, leptin, leptin receptor, and adiponectin receptor [
         <a href="#rid53">
          53
         </a>
         ]. Offspring of PCOS women treated with
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         did not demonstrate these changes, indicating that the PCOS intrauterine environment was responsible. Epigenomic changes induced by excess prenatal androgen exposure are discussed in the next section.
        </p>
        <p class="headingAnchor" id="H3622714551">
         <span class="h3">
          Congenital virilization
         </span>
         <span class="headingEndMark">
          —
         </span>
         PCOS is often observed in adolescents with congenital virilizing disorders, including congenital adrenal hyperplasia (CAH) [
         <a href="#rid1">
          1
         </a>
         ]. In untreated nonclassic CAH patients, hyperandrogenism is accompanied by significant insulin resistance [
         <a href="#rid54">
          54,55
         </a>
         ].
        </p>
        <p>
         Postnatal clinical markers of in utero androgen excess, such as anogenital distance and the ratio of the second-to-fourth digits of the hand (2D:4D), have been explored in offspring of women with PCOS, with mixed results [
         <a href="#rid1">
          1,56,57
         </a>
         ].
        </p>
        <p>
         Androgens induce epigenetic changes, both pre- and postnatally [
         <a href="#rid58">
          58,59
         </a>
         ]. Studies in nonhuman primates exposed to androgen excess early in gestation have yielded a model closely resembling PCOS. The critical window for androgen programming in rhesus monkeys is during early to mid-gestation [
         <a href="#rid1">
          1,58
         </a>
         ]. Prenatally androgenized female rhesus monkeys are born small and fat after experiencing compromised placental function and exhibit exaggerated weight gain during infancy [
         <a href="#rid60">
          60
         </a>
         ]. They then develop the characteristic reproductive features of PCOS, including ovarian and adrenal hyperandrogenism, oligomenorrhea, polyfollicular ovaries, elevated LH levels, and resistance to progesterone negative feedback on GnRH/LH secretion. They also have PCOS-like metabolic abnormalities, including truncal obesity, insulin resistance, impaired glucose tolerance, and dyslipidemia.
        </p>
        <p>
         Studies in prenatally androgenized rodent models of PCOS indicate that prenatal testosterone and dihydrotestosterone suppress the induction of hypothalamic progesterone receptors (PR) by estrogen; hypothalamic PR suppression persists postnatally and is associated with increased LH levels and pulsatility, absent LH surges, disrupted estrous cycles, and hyperandrogenemia in adulthood [
         <a href="#rid61">
          61-63
         </a>
         ]. These mice also developed a specific increase of GABAergic synapsing on GnRH neurons before puberty, and antiandrogen administration in adult mice restored both normal central GABAergic wiring and reproductive function [
         <a href="#rid63">
          63
         </a>
         ]. While the mechanism remains to be determined, this is a remarkable indication of central nervous system plasticity and reversibility of a PCOS-like state. Studies in neuron-specific AR knockout mice suggest that neuroendocrine signaling is a key mediator in the development of prenatally androgenized rodent models of PCOS [
         <a href="#rid64">
          64-66
         </a>
         ].
        </p>
        <p>
         The proposed role of epigenetics in PCOS has been bolstered by the observation that the prenatal effect of virilization is transgenerational in mice and related to epigenetic changes in PCOS daughters [
         <a href="#rid19">
          19
         </a>
         ]. Female mice with PCOS-like traits (with and without obesity) induced by prenatal androgenization were found to produce female offspring (the F
         <sub>
          3
         </sub>
         generation) with PCOS-like reproductive and metabolic traits. Common gene expression signatures were found in oocytes of F
         <sub>
          3
         </sub>
         mice and in blood cells of PCOS daughters and unrelated women with PCOS, including upregulation of the gene encoding TIAL1, an RNA-binding protein.
        </p>
        <p>
         Prenatal high-dose AMH administration to pregnant mice leads to PCOS features in their mature offspring [
         <a href="#rid67">
          67
         </a>
         ]. The mechanism primarily involves prenatal virilization via inhibition of maternal ovarian and placental aromatase [
         <a href="#rid67">
          67
         </a>
         ] and androgen action at the level of the fetal kisspeptin neuron [
         <a href="#rid65">
          65,66
         </a>
         ]. This mechanism may be pertinent to humans because second-trimester serum AMH levels are significantly, though only moderately, higher in pregnant PCOS than non-PCOS pregnant women [
         <a href="#rid67">
          67,68
         </a>
         ]. The first-, second-, and third-generation offspring of dams treated with high-dose AMH also have PCOS features [
         <a href="#rid69">
          69
         </a>
         ]. DNA methylation profiling of ovarian tissue of AMH-treated mice and their offspring demonstrated a large number of differentially expressed genes as well as an excess of hypomethylation. Upregulated genes were related to ovarian function, insulin action, inflammation, angiogenesis, cell-cycle progression, and axon guidance, whereas the top downregulated genes were related to epigenetic modifications or cell proliferation. Furthermore, administration of a universal methyl donor to affected offspring partially restored reproductive and metabolic traits. Several of the differentially methylated genes found in the ovaries of PCOS-like mice were also identified in blood from women with PCOS and in PCOS daughters [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         These observations demonstrate the potential for in utero exposures to permanently alter postnatal function via epigenetic reprogramming, while giving an early indication of plasticity of the peripubertal reproductive axis. While prenatal testosterone administration has proven to be a useful experimental tool for inducing a PCOS-phenotype in animal models, it is highly unlikely that intrauterine androgen excess either from the mother or from exogenous exposures underlies PCOS, due to the high expression of aromatase by the human placenta. The fetal ovary is also unlikely to be a source of excess androgen since it develops in the second trimester and is functionally quiescent [
         <a href="#rid1">
          1
         </a>
         ]. Congenital virilization in other model systems suggest that it is not increased androgens or AR activity per se, but rather a change in the level of one or more intermediates in the post-receptor androgen signaling pathway (eg, prostaglandins), which intersect with other effector pathways (eg, glutamate receptor signaling) to influence masculinization [
         <a href="#rid70">
          70,71
         </a>
         ]; in a neonatal brain virilization model, this has involved epigenetic alteration [
         <a href="#rid72">
          72
         </a>
         ]. Something similar may underlie the pathogenesis of PCOS.
        </p>
        <p class="headingAnchor" id="H2760239510">
         <span class="h3">
          Disturbed fetal nutrition
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is good evidence that fetal undernutrition predisposes to metabolic syndrome and related cardiovascular disease in adulthood; this association is sometimes termed the "Barker hypothesis," "fetal origins of adult disease," or "metabolic programming." It has been proposed that low birth weight is likewise a risk factor for PCOS [
         <a href="#rid73">
          73
         </a>
         ]. Other studies report an association with preterm birth rather than birth weight for gestational age, while others report none of these associations [
         <a href="#rid1">
          1,74
         </a>
         ].
        </p>
        <p>
         In some studies, high birth weight has also been associated with PCOS. However, most cases of PCOS in most populations occur in individuals with normal birth weight [
         <a href="#rid75">
          75,76
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5874.html" rel="external">
          "Definition, epidemiology, and etiology of obesity in children and adolescents", section on 'Metabolic programming'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H493072144">
         <span class="h2">
          Postnatal environment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postnatal environmental risk factors can be viewed as a second "hit," which cause a latent heritable or congenitally programmed susceptibility trait to manifest as PCOS  (
         <a class="graphic graphic_table graphicRef111333" href="/z/d/graphic/111333.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2989656973">
         <span class="h3">
          Insulin resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         All states of extreme insulin resistance (eg, insulin receptor loss-of-function mutations and generalized lipodystrophy) are associated with PCOS [
         <a href="#rid1">
          1
         </a>
         ]. Pseudo-Cushing's syndrome and pseudoacromegaly are two rare syndromes of intractable pediatric obesity that herald PCOS in adolescence. They are both characterized by moderately severe insulin resistance and compensatory hyperinsulinemia that cause obesity and overgrowth, respectively. (See
         <a class="local">
          'Insulin-resistant hyperinsulinism'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/125.html" rel="external">
          "Causes and pathophysiology of Cushing syndrome", section on 'Pseudo-Cushing syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1762.html" rel="external">
          "Insulin resistance: Definition and clinical spectrum", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         Simple (exogenous) obesity is the most common cause of insulin resistance. Childhood obesity has been identified as a risk factor for adult PCOS, according to a Bogalusa Heart Study substudy questionnaire [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         Insulin resistance is related to anovulation in women with PCOS (see
         <a class="local">
          'A unified concept of polycystic ovary syndrome pathophysiology'
         </a>
         below). Accordingly, anovulatory patients with PCOS are more insulin-resistant than are ovulatory patients with PCOS [
         <a href="#rid1">
          1,78
         </a>
         ] and anovulatory patients are more insulin-resistant, hyperinsulinemic, and dysglycemic, but not more hyperandrogenic, than oligo- or eumenorrheic patients [
         <a href="#rid79">
          79,80
         </a>
         ]. Any medical treatment or lifestyle modification that improves indices of insulin sensitivity in patients with PCOS also improves menstrual cyclicity and ovulatory function [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5853.html" rel="external">
          "Treatment of polycystic ovary syndrome in adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1069540605">
         <span class="h3">
          Hyperandrogenism
         </span>
         <span class="headingEndMark">
          —
         </span>
         In girls with poorly controlled congenital adrenal virilizing disorders such as CAH, the androgen excess causes ovarian hyperandrogenism and PCOM that is generally reversible when androgen levels are controlled with glucocorticoids [
         <a href="#rid81">
          81
         </a>
         ]; this is consistent with the PCOS-like state induced by peripubertal virilization of animal models that is reversible upon withdrawal of androgen, as discussed next [
         <a href="#rid58">
          58
         </a>
         ]. In some girls, however, ovarian hyperandrogenism persists, which seems to be due to the epigenetic reprogramming by congenital virilization discussed above.
        </p>
        <p>
         Peripubertal virilization of nonhuman primates and rodents causes a PCOS-like state that is reversible upon withdrawal of androgen [
         <a href="#rid58">
          58
         </a>
         ]. Studies in transgenic mice suggest that the brain is the key target: In peripubertally virilized mice, selective ablation of the AR in the brain completely or partially rescued the PCOS-like phenotype, whereas silencing of the AR in granulosa cells was not protective [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         Premature adrenarche may pose approximately a twofold increased risk for developing PCOS [
         <a href="#rid73">
          73
         </a>
         ]. Since the original observation [
         <a href="#rid73">
          73
         </a>
         ], follow-up studies in other populations have shown girls with premature adrenarche to have approximately a 25 percent prevalence of hirsutism and hyperandrogenemia in young adulthood but not a significant increase in oligomenorrhea [
         <a href="#rid82">
          82-84
         </a>
         ]. None of these later studies have determined the source of the hyperandrogenism or definitively ruled out mild adult PCOS phenotypes using Rotterdam criteria for PCOS, so the possibility of PCOS cannot be ruled out. (See
         <a class="medical medical_review" href="/z/d/html/5806.html" rel="external">
          "Premature adrenarche", section on 'Potential adult risks of premature adrenarche'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3692399914">
         <span class="h3">
          Other precipitants and risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The best support for a role of LH excess is in the setting of congenital virilization, in which there is prenatal reprogramming that may underpin LH excess at puberty. (See
         <a class="local">
          'Congenital virilization'
         </a>
         above.)
        </p>
        <p>
         Endocrine disruptors such as bisphenol A have been suspected of aggravating PCOS. While bisphenol A levels are slightly higher in individuals with PCOS compared with controls, there is no convincing human evidence that these minor differences are causally related to the development of PCOS [
         <a href="#rid85">
          85,86
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/111468.html" rel="external">
          "Occupational and environmental risks to reproduction in females: Specific exposures and impact", section on 'Bisphenol A and other phenols'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          A UNIFIED CONCEPT OF POLYCYSTIC OVARY SYNDROME PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 90 percent of individuals with PCOS have abnormal ovarian androgenic function [
         <a href="#rid1">
          1,27,87
         </a>
         ]. An abnormal degree of insulin resistance, obesity, or luteinizing hormone (LH) excess are each found in approximately one-half of cases. Thus, the common denominator in PCOS appears to be ovarian hyperandrogenism, with insulin-resistant hyperinsulinism being a nonessential but common aggravating factor in the pathophysiology. LH excess and the propensity to obesity seem to be secondary to the underlying ovarian hyperandrogenism and hyperinsulinism.
        </p>
        <p>
         We favor a unified minimal model of PCOS pathophysiology, which incorporates the major features of the syndrome into a parsimonious scheme [
         <a href="#rid1">
          1
         </a>
         ] and is shown in the figure  (
         <a class="graphic graphic_figure graphicRef111337" href="/z/d/graphic/111337.html" rel="external">
          figure 1
         </a>
         ). A brief overview:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Functional ovarian hyperandrogenism (FOH)
         </strong>
         – The model posits that FOH, which is found in the vast majority of cases, is the essence of PCOS. FOH can account for the essential clinical features of PCOS: hirsutism, oligo-anovulation, and polycystic ovaries.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In most individuals with PCOS, the cause of ovarian hyperandrogenism seems to be intrinsic to the ovary. In a small minority of individuals, modest hyperandrogenemia of extra-ovarian origin (adrenal or peripheral sources) causes anovulation and polycystic ovaries. (See
         <a class="local">
          'Secondary functional ovarian hyperandrogenism'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Insulin resistance, compensatory hyperinsulinism
         </strong>
         <strong>
          and obesity
         </strong>
         – Approximately one-half of cases of PCOS have insulin resistance with compensatory hyperinsulinemia. This hyperinsulinemia exerts paradoxical effects because insulin activity is tissue-specific: Hyperinsulinemia affects the ovary because it remains insulin-sensitive, whereas skeletal muscle and the liver demonstrate insulin resistance (see
         <a class="local">
          'Insulin-resistant hyperinsulinism'
         </a>
         below). In the ovary, hyperinsulinism synergizes with LH to upregulate androgen production and also causes premature luteinization of granulosa cells. These actions of insulin aggravate hyperandrogenism, development of polycystic ovary morphology (PCOM), and anovulation (see
         <a class="local">
          'Insulin-resistant hyperinsulinism'
         </a>
         below). Insulin-resistant hyperinsulinemia also promotes adiposity, which exacerbates the insulin-resistant state. (See
         <a class="local">
          'Associated pathophysiologic disturbances'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LH excess
         </strong>
         – The moderate hyperandrogenemia causes secondary LH elevation by interfering with progesterone negative feedback at the hypothalamic level. LH excess on its own is not likely to cause ovarian hyperandrogenism, because the ovary normally demonstrates homologous desensitization when exposed to high levels of LH. However, this protective mechanism is overridden in an environment of insulin excess (or increased
         <em>
          DENNDA1.V2
         </em>
         expression), wherein the ovary becomes hyperresponsive to LH and produces more androgens.
        </p>
        <p>
        </p>
        <p>
         These major features are discussed individually in the following sections.
        </p>
        <p class="headingAnchor" id="H1361087298">
         <span class="h2">
          Primary functional ovarian hyperandrogenism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 90 percent of PCOS patients have FOH, based on results of ovarian androgenic dynamic testing [
         <a href="#rid1">
          1,27,87
         </a>
         ]. FOH can account for the essential features of PCOS ( (
         <a class="graphic graphic_figure graphicRef111337" href="/z/d/graphic/111337.html" rel="external">
          figure 1
         </a>
         ), step 1). The excessive circulating androgens act on pilosebaceous units of the skin to cause the cutaneous manifestations of the syndrome, eg, hirsutism and acne. The excessive intraovarian androgenic milieu causes granulosa cell dysfunction, which manifests as oligo-anovulation and often PCOM. (See
         <a class="medical medical_review" href="/z/d/html/5852.html" rel="external">
          "Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         PCOS can be divided into several functional categories, representing different sources of androgen excess  (
         <a class="graphic graphic_table graphicRef94838" href="/z/d/graphic/94838.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_figure graphicRef94855" href="/z/d/graphic/94855.html" rel="external">
          figure 2
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Functionally typical PCOS/FOH – Two-thirds of cases are considered "functionally typical" because they demonstrate an exaggerated increase in 17-hydroxyprogesterone (17OHP) in response to LH receptor stimulation achieved clinically with either a gonadotropin-releasing hormone agonist (GnRHa) or with human chorionic gonadotropin. The increased 17OHP response appears to be an indicator of dysregulated cytochrome P450c17 function, as discussed next. In addition, these patients have an abnormal response to the
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         androgen-suppression test (DAST): Dexamethasone suppresses adrenocorticotropic hormone (ACTH)-dependent adrenocortical steroidogenesis but fails to suppress serum testosterone, consistent with an ovarian source. (See
         <a class="medical medical_review" href="/z/d/html/94182.html" rel="external">
          "Diagnostic evaluation of polycystic ovary syndrome in adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Functionally atypical PCOS – The remaining one-third of cases are considered "functionally atypical" because they have a normal 17OHP response to GnRHa or human chorionic gonadotropin but an abnormal response to DAST.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some patients with functionally atypical PCOS have isolated primary functional adrenal hyperandrogenism (FAH), demonstrated by ACTH stimulation testing, or PCOS without either FOH or FAH. Most of the latter group have the atypical PCOS of obesity, while a minority have idiopathic atypical PCOS  (
         <a class="graphic graphic_table graphicRef94838" href="/z/d/graphic/94838.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_figure graphicRef94855" href="/z/d/graphic/94855.html" rel="external">
          figure 2
         </a>
         ). Both groups are described below. (See
         <a class="local">
          'Functional adrenal hyperandrogenism'
         </a>
         below and
         <a class="local">
          'Obesity'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Mechanisms for FOH include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dysregulation of theca cell steroidogenesis
         </strong>
         — The pattern of steroid secretion in PCOS typically indicates generalized overactivity of the entire steroidogenic pathway from cholesterol to androgens and estrogens, with the prominent elevation in 17OHP indicating dysregulation of cytochrome P450c17 activities, which are encoded by the
         <em>
          CYP17A1
         </em>
         gene [
         <a href="#rid1">
          1,88
         </a>
         ]. Cytochrome P450c17 has both 17-hydroxylase and 17,20 lyase activity, and the latter is the rate-limiting step in androgen formation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Androgen production within the ovary is normally tightly regulated because androgen is a necessary evil in the ovary: Androgen is required as the substrate for estrogen formation, and androgen itself is required for optimal fertility [
         <a href="#rid1">
          1,89
         </a>
         ]. However, excessive androgen disrupts ovarian follicular development. At the small antral follicle stage of development, LH stimulates ovarian theca cells to form androgen and follicle-stimulating hormone (FSH) stimulates granulosa cells to form estrogen  (
         <a class="graphic graphic_figure graphicRef57364" href="/z/d/graphic/57364.html" rel="external">
          figure 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Normally, theca cell androgen production is coordinated with granulosa cell estrogen production by intraovarian (paracrine/autocrine) mechanisms rather than by endocrine negative feedback loops  (
         <a class="graphic graphic_figure graphicRef57364" href="/z/d/graphic/57364.html" rel="external">
          figure 3
         </a>
         ). Within the ovary, the response to LH is modulated by the balance between downregulation and upregulation processes. Downregulation results from desensitization of LH receptor-binding sites that occurs in the presence of elevated LH levels ("homologous desensitization") and by inhibition of P450c17 activities by local androgens and estrogens. Downregulation is counterbalanced by granulosa cell factors that upregulate P450c17 activities, particularly insulin-like growth factors (IGFs) and inhibin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This coordinated intraovarian regulation can be disrupted by extraovarian factors such as insulin and proinflammatory cytokines (eg, tumor necrosis factor [TNF]-alpha, transforming growth factor-beta, interleukin-1 and -6, and lipopolysaccharide) produced by specialized monocytic cells of adipose tissue and the gut microbiome. These also upregulate P450c17 activities, while other cytokines (eg, interleukin-22) downregulate androgenic enzymes [
         <a href="#rid90">
          90,91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In PCOS, downregulation of thecal androgen production is fundamentally flawed: PCOS ovaries are hyperresponsive to LH stimulation  (
         <a class="graphic graphic_figure graphicRef111337" href="/z/d/graphic/111337.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid1">
          1,88
         </a>
         ]. Three lines of evidence suggest that the dysregulation of steroidogenesis in PCOS is fundamentally of intrinsic ovarian origin [
         <a href="#rid1">
          1
         </a>
         ]. First, clinical studies in women with PCOS have demonstrated that FOH steroidogenic hypersensitivity to gonadotropin stimulation persists after prolonged gonadotropin suppression with GnRHa; there is also a parallel primary adrenal steroidogenic defect in some women, termed primary FAH, as discussed in the following sections. Second, in vitro studies have shown that the abnormal steroidogenic phenotype that is typical of PCOS theca cells persists in long-term culture, consistent with an intrinsic theca cell genetic defect. Third, genome-wide association studies (GWAS) have identified genetic linkage of PCOS to the DENND1A.V2 protein that reproduces the PCOS theca cell phenotype in vitro, as discussed above. (See
         <a class="local">
          'Genetic variation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Granulosa cell dysfunction
         </strong>
         – Granulosa cells line the antrum, or central fluid-filled cavity, of the growing ovarian follicle. They form estrogens from androgens (via expression of aromatase) and secrete peptides and growth factors that regulate follicle and oocyte development  (
         <a class="graphic graphic_figure graphicRef57364" href="/z/d/graphic/57364.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid92">
          92
         </a>
         ]. Androgen actions on granulosa cells are required for optimal follicle growth in response to gonadotropins [
         <a href="#rid1">
          1,89
         </a>
         ]. Androgens normally stimulate the transformation of primordial follicles from dormancy into primary follicles ("recruitment"), which is the first step in their growth and development into small antral follicles [
         <a href="#rid93">
          93
         </a>
         ]. Androgens then normally synergize with FSH to induce LH receptor expression on granulosa cells; this initiates "luteinization," which permits granulosa cells to form progesterone in response to LH and begins the formation of the preovulatory follicle [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In PCOS, excess intraovarian androgen causes the granulosa cell dysfunction that underlies anovulation and PCOM  (
         <a class="graphic graphic_figure graphicRef111337" href="/z/d/graphic/111337.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. High androgen levels stimulate an excessive number of small follicles to grow [
         <a href="#rid1">
          1
         </a>
         ]. This stimulation of early follicle growth, primarily resulting from increased granulosa cell proliferation, is most likely responsible for the increased anti-müllerian hormone (AMH) levels in women with PCOS; AMH is a product of the granulosa cells of small growing follicles that normally restrains primordial follicle growth ("recruitment") (see
         <a class="medical medical_review" href="/z/d/html/94182.html" rel="external">
          "Diagnostic evaluation of polycystic ovary syndrome in adolescents"
         </a>
         ). Androgens also contribute to the
         <strong>
          premature
         </strong>
         luteinization of the follicle, ie, granulosa cell luteinization occurs in the mid- rather than the late follicular phase, which seems to be the basis for the follicular maturation arrest that hinders the emergence of a dominant follicle and precludes ovulation [
         <a href="#rid94">
          94
         </a>
         ]. The increased proliferation of luteinized small follicles coupled with maturation arrest before the large antral stage of follicle development manifests as PCOM on ultrasound  (
         <a class="graphic graphic_figure graphicRef111337" href="/z/d/graphic/111337.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Alternatively, it is possible that granulosa cell dysfunction in PCOS is a manifestation of an intrinsic defect in the intraovarian (paracrine) regulation of follicle dynamics. For example, excessive granulosa cell secretion of factors such as inhibin B that stimulate androgens may reflect intrinsic granulosa cell dysfunction. Indeed, a subset of women with PCOS have deleterious variants in the genes encoding AMH or its receptor that impair restraint of follicular growth and granulosa cell aromatase activity; impaired AMH signaling has been postulated to underlie PCOS in these patients [
         <a href="#rid33">
          33
         </a>
         ], but it remains to be determined whether these patients are also atypical in having evidence of the premature ovarian failure characteristic of
         <em>
          Amh
         </em>
         null mouse models [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2444724126">
         <span class="h2">
          Insulin-resistant hyperinsulinism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Insulin resistance is an aggravating factor in approximately one-half of PCOS cases: The insulin resistance is disproportionately great for the severity of their obesity (body mass index) [
         <a href="#rid1">
          1,96,97
         </a>
         ]. Thus, in these women, insulin resistance is thought to be intrinsic. The other one-half of PCOS patients are no more insulin-resistant than otherwise healthy individuals with comparable body mass indexes.
        </p>
        <p>
         Because it is inconsistently present, insulin resistance does not account for the theca cell dysfunction characteristic of ordinary PCOS. Furthermore, the insulin resistance during the adolescent (developmental) phase of PCOS is usually mild. Insulin resistance only plays a primary pathogenic role in the development of PCOS in patients with severe or extreme insulin-resistance syndromes.
        </p>
        <p>
         The mechanism by which insulin resistance aggravates PCOS involves the compensatory hyperinsulinemia. The hyperinsulinemia that compensates for resistance to the glucose-metabolic effect of insulin is paradoxically responsible for excess insulin action in some tissues, most notably the ovary. This "insulin-resistant hyperinsulinism" is a major extraovarian factor in the pathophysiology of approximately one-half of the cases of PCOS.
        </p>
        <p>
         The insulin resistance of PCOS is remarkable because resistance to the metabolic effects of insulin is tissue-specific [
         <a href="#rid1">
          1
         </a>
         ]. While skeletal muscle is resistant to insulin action on glucose metabolism due to mitochondrial-associated gene dysfunction [
         <a href="#rid98">
          98
         </a>
         ], the compensatory hyperinsulinemia elicits excess insulin action in the ovary, liver, and adipocytes [
         <a href="#rid99">
          99
         </a>
         ]. Thus, signaling pathways mediating mitogenic, growth factor-like, protein-anabolic, and lipogenic actions of insulin remain sensitive to insulin. These actions of insulin aggravate the steroidogenic dysregulation and contribute to the obesity and acanthosis nigricans that are common comorbidities of PCOS.
        </p>
        <p>
         This insulin-resistant hyperinsulinism, when present, is an important aggravating factor in PCOS pathogenesis because it promotes FOH: The hyperinsulinemia sensitizes the intrinsically dysregulated ovarian theca cells to secrete excess androgen in response to LH [
         <a href="#rid1">
          1
         </a>
         ] ( (
         <a class="graphic graphic_figure graphicRef111337" href="/z/d/graphic/111337.html" rel="external">
          figure 1
         </a>
         ), step 2). It does this by reversing the LH-induced homologous desensitization of LH-binding sites, which then upregulates cytochrome P450c17 activities  (
         <a class="graphic graphic_figure graphicRef57364" href="/z/d/graphic/57364.html" rel="external">
          figure 3
         </a>
         ). Insulin also upregulates testosterone formation by type 5 17-beta-hydroxysteroid dehydrogenase via a transcription factor (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F606465&amp;token=87jLzclRwWxNoI%2BQq5Gg7xeuHpRrol9jV3P%2FMXUwLBFbchJ6ixS8GJkxDmDnoFHc&amp;TOPIC_ID=5799" target="_blank">
          KLF15
         </a>
         ) that stimulates adipogenesis [
         <a href="#rid100">
          100
         </a>
         ]. Insulin excess also synergizes with androgen excess and FSH to prematurely induce LH receptors on granulosa cells, leading to their premature luteinization and follicle maturation arrest [
         <a href="#rid1">
          1,94
         </a>
         ]. The severity of insulin resistance correlates with the severity of hyperandrogenism, severity of anovulatory symptomatology, and prevalence of PCOM. Any treatment that lowers insulin levels therefore improves hyperandrogenism (including in experimental models of PCOS [
         <a href="#rid101">
          101
         </a>
         ]), though the hyperandrogenism of typical PCOS is seldom fully corrected by such treatments alone in most populations.
        </p>
        <p>
         One of the great mysteries about PCOS is whether the hyperandrogenism might cause insulin resistance. Androgens in vitro exert some anti-insulin effects [
         <a href="#rid102">
          102
         </a>
         ]. A variety of studies indicate that administration of oral androgens or virilizing doses of androgen to humans causes insulin resistance [
         <a href="#rid102">
          102,103
         </a>
         ]. The induction of modest hyperandrogenism does not cause insulin resistance in women [
         <a href="#rid104">
          104
         </a>
         ], but in adult nonhuman primates, it will induce insulin resistance when combined with an obesogenic diet [
         <a href="#rid105">
          105,106
         </a>
         ]. However, reversal of PCOS androgen excess has not ameliorated insulin resistance in the majority of studies [
         <a href="#rid107">
          107
         </a>
         ]. In animal models, androgens permanently program insulin resistance when given transiently prenatally. (See
         <a class="local">
          'Congenital virilization'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H703072287">
         <span class="h2">
          Associated pathophysiologic disturbances
         </span>
         <span class="headingEndMark">
          —
         </span>
         Excess gonadotropin secretion, adiposity, and adrenal androgenic dysfunction are inconsistent features of PCOS that seem related to dysregulation of steroidogenesis and/or insulin-resistant hyperinsulinism.
        </p>
        <p class="headingAnchor" id="H583113021">
         <span class="h3">
          Gonadotropin abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         LH is necessary for the expression of steroidogenic enzymes. Thus, PCOS is a gonadotropin-dependent, ie, functional, form of ovarian hyperandrogenism. Any treatment that suppresses LH levels (eg, estrogen-progestin oral contraceptives) suppresses ovarian hyperandrogenism [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Increased LH, often accompanied by decreased FSH, was the first laboratory abnormality identified in classic PCOS and was historically thought to play a role in its pathogenesis by increasing ovarian androgen production. Subsequent research showed that serum LH is elevated in only approximately one-half of PCOS patients with documented FOH [
         <a href="#rid1">
          1
         </a>
         ]. Furthermore, the homologous desensitization phenomenon limits ovarian androgen excess in response to excess LH, except in the presence of insulin-resistant hyperinsulinism.
        </p>
        <p>
         Evidence suggests that the increased LH observed in patients with PCOS is primarily caused by androgen interference with progesterone negative feedback [
         <a href="#rid1">
          1
         </a>
         ]. This resistance is overcome by antiandrogen treatment [
         <a href="#rid108">
          108
         </a>
         ]. Resistance to estrogen-progesterone negative feedback, while significant, occurs in less than one-half of adolescents with PCOS, in contrast with almost all adults [
         <a href="#rid109">
          109
         </a>
         ]. This discrepancy between adolescents and adults suggests that this resistance only becomes apparent when the high sensitivity to sex-steroid negative feedback of childhood fully wanes with maturity.
        </p>
        <p>
         Such data suggest that LH excess in PCOS is the result, rather than the cause, of androgen excess.
        </p>
        <p>
         In more severe cases of PCOS, the moderate testosterone excess stimulates LH secretion ( (
         <a class="graphic graphic_figure graphicRef111337" href="/z/d/graphic/111337.html" rel="external">
          figure 1
         </a>
         ), step 3). Additionally, granulosa cells that have been prematurely luteinized, under the influence of both increased testosterone and insulin levels (see
         <a class="local">
          'Insulin resistance'
         </a>
         above), begin to secrete estrogen in response to LH as well as to FSH. The negative feedback effect of the resultant estradiol excess can account for the significantly low FSH levels of PCOS ( (
         <a class="graphic graphic_figure graphicRef111337" href="/z/d/graphic/111337.html" rel="external">
          figure 1
         </a>
         ), step 4).
        </p>
        <p class="headingAnchor" id="H1647712375">
         <span class="h3">
          Obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately one-half of PCOS patients are obese, and at least one-third of nonobese PCOS patients have increased intraabdominal fat [
         <a href="#rid1">
          1,110
         </a>
         ].
        </p>
        <p>
         The reason for the high prevalence of obesity in PCOS is not entirely clear. The hyperinsulinism of insulin resistance seems to be an important factor since in vitro studies indicate that insulin signaling in human subcutaneous adipose tissue is intact in PCOS [
         <a href="#rid1">
          1,111
         </a>
         ]. Insulin signaling is of major importance to the size and function of the white adipose tissue depot: It stimulates adipogenesis (differentiation of preadipocytes into adipocytes) and lipogenesis, while inhibiting lipolysis [
         <a href="#rid111">
          111-113
         </a>
         ]. Androgens oppose insulin effects on subcutaneous fat stores, in part by impairing pluripotent mesenchymal stem cell differentiation into the preadipocyte lineage, instead favoring a myogenic differentiation [
         <a href="#rid12">
          12,55
         </a>
         ]. However, mild hyperandrogenemia also promotes visceral fat accumulation, which promotes insulin resistance [
         <a href="#rid49">
          49,55,114
         </a>
         ]. There also appear to be inherent differences in the subcutaneous abdominal fat cells of normal-weight and obese women with PCOS; normal-weight women are able to form small adipocytes in subcutaneous fat depots that retain insulin sensitivity [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Obesity aggravates the clinical severity of FOH by increasing insulin resistance ( (
         <a class="graphic graphic_figure graphicRef111337" href="/z/d/graphic/111337.html" rel="external">
          figure 1
         </a>
         ), panel B). In PCOS, visceral fat contributes more to insulin resistance than does subcutaneous abdominal fat because of its enhanced lipolytic response to catecholamines (the major lipolytic stimulus in humans) [
         <a href="#rid1">
          1
         </a>
         ]. Enhanced visceral fat lipolysis is unique to PCOS and not attributable to androgen excess [
         <a href="#rid115">
          115,116
         </a>
         ]; the free fatty acids and diacylglycerol released from visceral fat appear to promote insulin resistance in the liver and muscle, respectively. (See
         <a class="medical medical_review" href="/z/d/html/1810.html" rel="external">
          "Pathogenesis of type 2 diabetes mellitus", section on 'Role of diet, obesity, and inflammation'
         </a>
         .)
        </p>
        <p>
         The mechanisms by which obesity causes insulin resistance include a deficiency of insulin-sensitizing adipokines such as adiponectin in favor of proinflammatory cytokines such as TNF-alpha that are secreted by a unique population of adipose tissue-derived, monocytic, regulatory T cells [
         <a href="#rid117">
          117-119
         </a>
         ] and by an altered intestinal microbiome [
         <a href="#rid90">
          90,91
         </a>
         ]. Inflammatory cytokines not only cause insulin resistance, they also aggravate ovarian hyperandrogenism. Hyperandrogenism, in turn, sensitizes circulating mononuclear cells to secrete inflammatory cytokines in response to glucose and saturated fat ingestion [
         <a href="#rid1">
          1,120
         </a>
         ], which, in a vicious cycle, aggravates hyperandrogenism and insulin resistance [
         <a href="#rid121">
          121,122
         </a>
         ].
        </p>
        <p>
         Obesity also causes low microbial diversity of the intestinal microbiome, which results in a "leaky gut" and resultant endotoxemia [
         <a href="#rid123">
          123,124
         </a>
         ]. This "leaky gut" leads to increased serum lipopolysaccharide, interleukin-1-beta, and TNF-alpha levels, which directly stimulate thecal androgen production [
         <a href="#rid90">
          90,123
         </a>
         ]. Dysbiosis is also found in nonobese PCOS, indicating that hyperandrogenism is a causative factor [
         <a href="#rid125">
          125
         </a>
         ].
        </p>
        <p>
         In contrast with energy-storing white adipose tissue, women with PCOS have been shown to have less energy-consuming brown adipose tissue [
         <a href="#rid126">
          126,127
         </a>
         ]. Study of the regulation of brown fat development is in its infancy [
         <a href="#rid128">
          128
         </a>
         ].
        </p>
        <p>
         In addition to aggravating PCOS via insulin resistance, obesity seems to be the sole cause of most functionally atypical PCOS (sometimes termed "atypical PCOS of obesity")  (
         <a class="graphic graphic_table graphicRef94838" href="/z/d/graphic/94838.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_figure graphicRef94855" href="/z/d/graphic/94855.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. Both androgen and estrogen are formed in excess by the adipose tissue of obese women [
         <a href="#rid100">
          100,129-131
         </a>
         ]. Obesity also suppresses gonadotropin levels by accelerating their metabolism [
         <a href="#rid132">
          132,133
         </a>
         ]. Thus, obesity should be suspected as the cause of menstrual irregularity when dehydroepiandrosterone sulfate (DHEAS) and LH are normal in obese PCOS women with marginally elevated testosterone levels.
        </p>
        <p class="headingAnchor" id="H1658030808">
         <span class="h3">
          Functional adrenal hyperandrogenism
         </span>
         <span class="headingEndMark">
          —
         </span>
         In 25 to 50 percent of cases, primary FOH is accompanied by a seemingly related primary FAH. In another 5 percent of cases of PCOS, FAH is the only detectable source of androgen excess  (
         <a class="graphic graphic_table graphicRef94838" href="/z/d/graphic/94838.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_figure graphicRef94855" href="/z/d/graphic/94855.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_table graphicRef91894" href="/z/d/graphic/91894.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. Isolated primary FAH usually occurs in hirsute women without menstrual abnormalities, ie, without PCOS.
        </p>
        <p>
         Primary FAH is defined as 17-ketosteroid hyperresponsiveness to ACTH that is otherwise unexplained. The steroidogenic pattern of response to ACTH resembles an exaggerated adrenarche and, in the past, was confused with nonclassic 3-beta-hydroxysteroid dehydrogenase deficiency (see
         <a class="medical medical_review" href="/z/d/html/5852.html" rel="external">
          "Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents"
         </a>
         ). DHEA is the major hyperresponsive 17-ketosteroid and is correlated with 17-hydroxypregnenolone responses. This FAH has been postulated to result from a dysregulation of adrenal zona reticularis steroidogenesis that parallels the dysregulation of ovarian theca cell steroidogenesis [
         <a href="#rid1">
          1,134
         </a>
         ]. This FAH has been associated with mild adrenal enlargement in some cases [
         <a href="#rid135">
          135
         </a>
         ] but also with slightly smaller adrenal volumes and a marginal degree of autonomous adrenocortical function in others [
         <a href="#rid136">
          136
         </a>
         ]. Hyperinsulinism seems to aggravate FAH as it does FOH [
         <a href="#rid137">
          137
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3542454697">
         <span class="h2">
          Secondary functional ovarian hyperandrogenism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperandrogenic anovulation may be explained by a variety of relatively uncommon disorders  (
         <a class="graphic graphic_table graphicRef91894" href="/z/d/graphic/91894.html" rel="external">
          table 3
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/5852.html" rel="external">
          "Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents"
         </a>
         ). Several such disorders are capable of causing secondary FOH.
        </p>
        <p>
         Virilizing disorders, the most common of which is virilizing congenital adrenal hyperplasia (CAH), can cause hyperandrogenic anovulation with PCOM and FOH in a combination of ways [
         <a href="#rid1">
          1,81
         </a>
         ]. The mechanisms include both congenital virilization, which programs for PCOS at puberty regardless of how well postnatal virilization is controlled (see
         <a class="local">
          'Etiology'
         </a>
         above), and uncontrolled hyperandrogenism, which causes PCOM and follicle maturation arrest. Rarely, patients with CAH have ectopic adrenal rest tissue, which is sensitive to LH and causes hyperandrogenism that cannot be controlled by adrenal suppression [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
         PCOS due to secondary FOH is also seen in any disorder that causes extreme insulin resistance and hyperinsulinemia, for example, insulin-receptor mutations (where extreme hyperinsulinemia activates the IGF-1 receptor) and generalized lipodystrophy [
         <a href="#rid1">
          1
         </a>
         ]. In these cases, PCOS features may appear as early as the neonatal period or early childhood. A significant elevation of serum IGF-1 accounts for the secondary FOH of acromegaly [
         <a href="#rid138">
          138
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          Valproic acid
         </a>
         , an antiseizure medication, directly augments the transcription of the steroidogenic gene
         <em>
          CYP17
         </em>
         that encodes cytochrome P450c17 and can cause hyperandrogenic anovulation and PCOM. (See
         <a class="medical medical_review" href="/z/d/html/5852.html" rel="external">
          "Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H820932694">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110097.html" rel="external">
          "Society guideline links: Polycystic ovary syndrome"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/110632.html" rel="external">
          "Society guideline links: Hirsutism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23417457">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical significance
         </strong>
         – Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory symptoms and hyperandrogenism in women, and symptoms typically first manifest during adolescence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contributing risk factors
         </strong>
         – PCOS seems to arise as a complex trait that results from the interaction of diverse genetic and environmental factors that usually first manifest when mature gonadotropin levels are achieved at puberty. Obesity is the most common postnatal environmental contributor. (See
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology
         </strong>
         – The pathophysiology of PCOS usually includes excess ovarian androgen production (functional ovarian hyperandrogenism [FOH]), with or without insulin-resistant hyperinsulinism or functional adrenal hyperandrogenism (FAH)  (
         <a class="graphic graphic_figure graphicRef111337" href="/z/d/graphic/111337.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef94855" href="/z/d/graphic/94855.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="local">
          'A unified concept of polycystic ovary syndrome pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          FOH
         </strong>
         – Excess ovarian androgen production (FOH) is present in most cases and typically arises from dysregulation of steroidogenesis that includes an increased sensitivity to luteinizing hormone (LH) ( (
         <a class="graphic graphic_figure graphicRef111337" href="/z/d/graphic/111337.html" rel="external">
          figure 1
         </a>
         ), step 1). (See
         <a class="local">
          'Primary functional ovarian hyperandrogenism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          FAH
         </strong>
         – In 25 to 50 percent of cases, primary FOH is accompanied by a functionally related primary FAH  (
         <a class="graphic graphic_figure graphicRef94855" href="/z/d/graphic/94855.html" rel="external">
          figure 2
         </a>
         ). In approximately 5 percent, FAH is present without FOH. (See
         <a class="local">
          'Functional adrenal hyperandrogenism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Insulin-resistant hyperinsulinism
         </strong>
         – In approximately 50 percent of cases, PCOS is associated with a selective form of insulin resistance, in which muscle is resistant to the metabolic effects of insulin, while the ovaries, adrenals, and adipose tissue remain relatively sensitive to insulin, thereby promoting androgen production and obesity in response to compensatory hyperinsulinemia ( (
         <a class="graphic graphic_figure graphicRef111337" href="/z/d/graphic/111337.html" rel="external">
          figure 1
         </a>
         ), step 2). (See
         <a class="local">
          'Insulin-resistant hyperinsulinism'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev 2016; 37:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fauser BC, Bouchard P. Uncertainty remains in women with PCOS regarding the increased incidence of cardiovascular disease later in life, despite the indisputable presence of multiple cardiovascular risk factors at a young age. J Clin Endocrinol Metab 2011; 96:3675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Twig G, Yaniv G, Levine H, et al. Body-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood. N Engl J Med 2016; 374:2430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berni TR, Morgan CL, Rees DA. Women With Polycystic Ovary Syndrome Have an Increased Risk of Major Cardiovascular Events: a Population Study. J Clin Endocrinol Metab 2021; 106:e3369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen H, Zhang Y, Li S, et al. The Genetic Association of Polycystic Ovary Syndrome and the Risk of Endometrial Cancer: A Mendelian Randomization Study. Front Endocrinol (Lausanne) 2021; 12:756137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hazelwood E, Sanderson E, Tan VY, et al. Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis. BMC Med 2022; 20:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu T, Goodarzi MO. Causes and Consequences of Polycystic Ovary Syndrome: Insights From Mendelian Randomization. J Clin Endocrinol Metab 2022; 107:e899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colilla S, Cox NJ, Ehrmann DA. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab 2001; 86:2027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu J, Pujol-Gualdo N, Wittemans LBL, et al. Evidence From Men for Ovary-independent Effects of Genetic Risk Factors for Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2022; 107:e1577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbott DH, Rayome BH, Dumesic DA, et al. Clustering of PCOS-like traits in naturally hyperandrogenic female rhesus monkeys. Hum Reprod 2017; 32:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 2006; 91:2100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumesic DA, Abbott DH, Sanchita S, Chazenbalk GD. Endocrine-Metabolic Dysfunction in Polycystic Ovary Syndrome: an Evolutionary Perspective. Curr Opin Endocr Metab Res 2020; 12:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumesic DA, Padmanabhan V, Chazenbalk GD, Abbott DH. Polycystic ovary syndrome as a plausible evolutionary outcome of metabolic adaptation. Reprod Biol Endocrinol 2022; 20:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leibel NI, Baumann EE, Kocherginsky M, Rosenfield RL. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. J Clin Endocrinol Metab 2006; 91:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahsar-Miller MD, Nixon C, Boots LR, et al. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 2001; 75:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sam S, Legro RS, Essah PA, et al. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci U S A 2006; 103:7030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sir-Petermann T, Codner E, Pérez V, et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94:1923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maliqueo M, Sir-Petermann T, Pérez V, et al. Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94:3282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Risal S, Pei Y, Lu H, et al. Prenatal androgen exposure and transgenerational susceptibility to polycystic ovary syndrome. Nat Med 2019; 25:1894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carey AH, Chan KL, Short F, et al. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol (Oxf) 1993; 38:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Govind A, Obhrai MS, Clayton RN. Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. J Clin Endocrinol Metab 1999; 84:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franks S, Webber LJ, Goh M, et al. Ovarian morphology is a marker of heritable biochemical traits in sisters with polycystic ovaries. J Clin Endocrinol Metab 2008; 93:3396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coviello AD, Zhuang WV, Lunetta KL, et al. Circulating testosterone and SHBG concentrations are heritable in women: the Framingham Heart Study. J Clin Endocrinol Metab 2011; 96:E1491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legro RS, Driscoll D, Strauss JF 3rd, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 1998; 95:14956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu DM, Torchen LC, Sung Y, et al. Evidence for gonadotrophin secretory and steroidogenic abnormalities in brothers of women with polycystic ovary syndrome. Hum Reprod 2014; 29:2764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crisosto N, Echiburú B, Maliqueo M, et al. Reproductive and metabolic features during puberty in sons of women with polycystic ovary syndrome. Endocr Connect 2017; 6:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenfield RL, Mortensen M, Wroblewski K, et al. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod 2011; 26:3138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almawi WY, Gammoh E, Malalla ZH, Al-Madhi SA. Analysis of VEGFA Variants and Changes in VEGF Levels Underscores the Contribution of VEGF to Polycystic Ovary Syndrome. PLoS One 2016; 11:e0165636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li L, Zhang J, Deng Q, et al. Proteomic Profiling for Identification of Novel Biomarkers Differentially Expressed in Human Ovaries from Polycystic Ovary Syndrome Patients. PLoS One 2016; 11:e0164538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu HY, Huang YL, Liu JQ, Huang Q. Transcription factor‑microRNA synergistic regulatory network revealing the mechanism of polycystic ovary syndrome. Mol Med Rep 2016; 13:3920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ding Y, Zhuo G, Zhang C, Leng J. Point mutation in mitochondrial tRNA gene is associated with polycystic ovary syndrome and insulin resistance. Mol Med Rep 2016; 13:3169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mykhalchenko K, Lizneva D, Trofimova T, et al. Genetics of polycystic ovary syndrome. Expert Rev Mol Diagn 2017; 17:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorsic LK, Dapas M, Legro RS, et al. Functional Genetic Variation in the Anti-Müllerian Hormone Pathway in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2019; 104:2855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghidei L, Bruno-Gaston JA, Guner JZ, Dietrich JE. Prevalence of Polycystic Ovary Syndrome in Patients With McCune Albright Syndrome. J Pediatr Adolesc Gynecol 2022; 35:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Day F, Karaderi T, Jones MR, et al. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet 2018; 14:e1007813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAllister JM, Han AX, Modi BP, et al. miRNA Profiling Reveals miRNA-130b-3p Mediates DENND1A Variant 2 Expression and Androgen Biosynthesis. Endocrinology 2019; 160:1964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodarzi MO, Jones MR, Li X, et al. Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J Med Genet 2012; 49:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen ZJ, Zhao H, He L, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 2011; 43:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dallel M, Sarray S, Douma Z, et al. Differential association of DENND1A genetic variants with polycystic ovary syndrome in Tunisian but not Bahraini Arab women. Gene 2018; 647:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tee MK, Speek M, Legeza B, et al. Alternative splicing of DENND1A, a PCOS candidate gene, generates variant 2. Mol Cell Endocrinol 2016; 434:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teves ME, Modi BP, Kulkarni R, et al. Human DENND1A.V2 Drives Cyp17a1 Expression and Androgen Production in Mouse Ovaries and Adrenals. Int J Mol Sci 2020; 21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dapas M, Sisk R, Legro RS, et al. Family-Based Quantitative Trait Meta-Analysis Implicates Rare Noncoding Variants in DENND1A in Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2019; 104:3835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dapas M, Lin FTJ, Nadkarni GN, et al. Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis. PLoS Med 2020; 17:e1003132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gao L, Wu D, Wu Y, et al. MiR-3940-5p promotes granulosa cell proliferation through targeting KCNA5 in polycystic ovarian syndrome. Biochem Biophys Res Commun 2020; 524:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nanda D, Chandrasekaran SP, Ramachandran V, et al. Evaluation of Serum miRNA-24, miRNA-29a and miRNA-502-3p Expression in PCOS Subjects: Correlation with Biochemical Parameters Related to PCOS and Insulin Resistance. Indian J Clin Biochem 2020; 35:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang X, Xiao H, Zhang X, et al. Decreased microRNA-125b-5p disrupts follicle steroidogenesis through targeting PAK3/ERK1/2 signalling in mouse preantral follicles. Metabolism 2020; 107:154241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulkarni R, Teves ME, Han AX, et al. Colocalization of Polycystic Ovary Syndrome Candidate Gene Products in Theca Cells Suggests Novel Signaling Pathways. J Endocr Soc 2019; 3:2204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romero-Ruiz A, Pineda B, Ovelleiro D, et al. Molecular diagnosis of polycystic ovary syndrome in obese and non-obese women by targeted plasma miRNA profiling. Eur J Endocrinol 2021; 185:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carbone L, Davis BA, Fei SS, et al. Synergistic Effects of Hyperandrogenemia and Obesogenic Western-style Diet on Transcription and DNA Methylation in Visceral Adipose Tissue of Nonhuman Primates. Sci Rep 2019; 9:19232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang F, Pan J, Liu Y, et al. Alternative splicing of the androgen receptor in polycystic ovary syndrome. Proc Natl Acad Sci U S A 2015; 112:4743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tian L, Zou Y, Tan J, et al. Androgen receptor gene mutations in 258 Han Chinese patients with polycystic ovary syndrome. Exp Ther Med 2021; 21:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vázquez-Martínez ER, Gómez-Viais YI, García-Gómez E, et al. DNA methylation in the pathogenesis of polycystic ovary syndrome. Reproduction 2019; 158:R27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Echiburú B, Milagro F, Crisosto N, et al. DNA methylation in promoter regions of genes involved in the reproductive and metabolic function of children born to women with PCOS. Epigenetics 2020; 15:1178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Speiser PW, Serrat J, New MI, Gertner JM. Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992; 75:1421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffer L, Kempegowda P, Arlt W, O'Reilly MW. MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease. Eur J Endocrinol 2017; 177:R125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kosidou K, Dalman C, Widman L, et al. Maternal polycystic ovary syndrome and the risk of autism spectrum disorders in the offspring: a population-based nationwide study in Sweden. Mol Psychiatry 2016; 21:1441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Homburg R, Gudi A, Shah A, M Layton A. A novel method to demonstrate that pregnant women with polycystic ovary syndrome hyper-expose their fetus to androgens as a possible stepping stone for the developmental theory of PCOS. A pilot study. Reprod Biol Endocrinol 2017; 15:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stener-Victorin E, Padmanabhan V, Walters KA, et al. Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome. Endocr Rev 2020; 41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salinas I, Sinha N, Sen A. Androgen-induced epigenetic modulations in the ovary. J Endocrinol 2021; 249:R53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbott DH. Does a compromised placenta contribute to transgenerational transmission of metabolic dysfunction in polycystic ovary syndrome? Fertil Steril 2020; 113:1165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foecking EM, Szabo M, Schwartz NB, Levine JE. Neuroendocrine consequences of prenatal androgen exposure in the female rat: absence of luteinizing hormone surges, suppression of progesterone receptor gene expression, and acceleration of the gonadotropin-releasing hormone pulse generator. Biol Reprod 2005; 72:1475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore AM, Prescott M, Marshall CJ, et al. Enhancement of a robust arcuate GABAergic input to gonadotropin-releasing hormone neurons in a model of polycystic ovarian syndrome. Proc Natl Acad Sci U S A 2015; 112:596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silva MS, Prescott M, Campbell RE. Ontogeny and reversal of brain circuit abnormalities in a preclinical model of PCOS. JCI Insight 2018; 3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caldwell ASL, Edwards MC, Desai R, et al. Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome. Proc Natl Acad Sci U S A 2017; 114:E3334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore AM, Lohr DB, Coolen LM, Lehman MN. Prenatal Androgen Exposure Alters KNDy Neurons and Their Afferent Network in a Model of Polycystic Ovarian Syndrome. Endocrinology 2021; 162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho EV, Shi C, Cassin J, et al. Reproductive Deficits Induced by Prenatal Antimüllerian Hormone Exposure Require Androgen Receptor in Kisspeptin Cells. Endocrinology 2021; 162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tata B, Mimouni NEH, Barbotin AL, et al. Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nat Med 2018; 24:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piltonen TT, Giacobini P, Edvinsson Å, et al. Circulating antimüllerian hormone and steroid hormone levels remain high in pregnant women with polycystic ovary syndrome at term. Fertil Steril 2019; 111:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mimouni NEH, Paiva I, Barbotin AL, et al. Polycystic ovary syndrome is transmitted via a transgenerational epigenetic process. Cell Metab 2021; 33:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta C, Goldman AS. The arachidonic acid cascade is involved in the masculinizing action of testosterone on embryonic external genitalia in mice. Proc Natl Acad Sci U S A 1986; 83:4346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright CL, McCarthy MM. Prostaglandin E2-induced masculinization of brain and behavior requires protein kinase A, AMPA/kainate, and metabotropic glutamate receptor signaling. J Neurosci 2009; 29:13274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nugent BM, Wright CL, Shetty AC, et al. Brain feminization requires active repression of masculinization via DNA methylation. Nat Neurosci 2015; 18:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ibáñez L, Potau N, Francois I, de Zegher F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab 1998; 83:3558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paalanne M, Vääräsmäki M, Mustaniemi S, et al. Clinical and biochemical signs of polycystic ovary syndrome in young women born preterm. Eur J Endocrinol 2021; 185:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fulghesu AM, Manca R, Loi S, Fruzzetti F. Insulin resistance and hyperandrogenism have no substantive association with birth weight in adolescents with polycystic ovary syndrome. Fertil Steril 2015; 103:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paschou SA, Ioannidis D, Vassilatou E, et al. Birth weight and polycystic ovary syndrome in adult life: is there a causal link? PLoS One 2015; 10:e0122050.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           He Y, Tian J, Blizzard L, et al. Associations of childhood adiposity with menstrual irregularity and polycystic ovary syndrome in adulthood: the Childhood Determinants of Adult Health Study and the Bogalusa Heart Study. Hum Reprod 2020; 35:1185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson S, Kiddy D, Gelding SV, et al. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol (Oxf) 1993; 39:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ezeh U, Ezeh C, Pisarska MD, Azziz R. Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism. Fertil Steril 2021; 115:1557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ezeh U, Pisarska MD, Azziz R. Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome. Hum Reprod 2022; 37:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnes RB, Rosenfield RL, Ehrmann DA, et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 1994; 79:1328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenfield RL. Normal and Premature Adrenarche. Endocr Rev 2021; 42:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tennilä J, Jääskeläinen J, Utriainen P, et al. PCOS Features and Steroid Profiles Among Young Adult Women with a History of Premature Adrenarche. J Clin Endocrinol Metab 2021; 106:e3335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Livadas S, Bothou C, Kanaka-Gantenbein C, et al. Unfavorable Hormonal and Psychologic Profile in Adult Women with a History of Premature Adrenarche and Pubarche, Compared to Women with Polycystic Ovary Syndrome. Horm Metab Res 2020; 52:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hewlett M, Chow E, Aschengrau A, Mahalingaiah S. Prenatal Exposure to Endocrine Disruptors: A Developmental Etiology for Polycystic Ovary Syndrome. Reprod Sci 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutkowska AZ, Diamanti-Kandarakis E. Polycystic ovary syndrome and environmental toxins. Fertil Steril 2016; 106:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirshfeld-Cytron J, Barnes RB, Ehrmann DA, et al. Characterization of functionally typical and atypical types of polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94:1587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995; 16:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sen A, Hammes SR. Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. Mol Endocrinol 2010; 24:1393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox CW, Zhang L, Sohni A, et al. Inflammatory Stimuli Trigger Increased Androgen Production and Shifts in Gene Expression in Theca-Interstitial Cells. Endocrinology 2019; 160:2946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qi X, Yun C, Sun L, et al. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat Med 2019; 25:1225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsueh AJ, Kawamura K, Cheng Y, Fauser BC. Intraovarian control of early folliculogenesis. Endocr Rev 2015; 36:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vendola KA, Zhou J, Adesanya OO, et al. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998; 101:2622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willis DS, Watson H, Mason HD, et al. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J Clin Endocrinol Metab 1998; 83:3984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durlinger AL, Kramer P, Karels B, et al. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology 1999; 140:5789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38:1165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JY, Tfayli H, Michaliszyn SF, Arslanian S. Impaired Lipolysis, Diminished Fat Oxidation, and Metabolic Inflexibility in Obese Girls With Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2018; 103:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreno-Asso A, Altıntaş A, McIlvenna LC, et al. Non-cell autonomous mechanisms control mitochondrial gene dysregulation in polycystic ovary syndrome. J Mol Endocrinol 2021; 68:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cree-Green M, Rahat H, Newcomer BR, et al. Insulin Resistance, Hyperinsulinemia, and Mitochondria Dysfunction in Nonobese Girls With Polycystic Ovarian Syndrome. J Endocr Soc 2017; 1:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Du X, Rosenfield RL, Qin K. KLF15 Is a transcriptional regulator of the human 17beta-hydroxysteroid dehydrogenase type 5 gene. A potential link between regulation of testosterone production and fat stores in women. J Clin Endocrinol Metab 2009; 94:2594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuan X, Hu T, Zhao H, et al. Brown adipose tissue transplantation ameliorates polycystic ovary syndrome. Proc Natl Acad Sci U S A 2016; 113:2708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corbould A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J Endocrinol 2007; 192:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008; 93:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang G, Tang E, Aakil A, et al. Testosterone dose-response relationships with cardiovascular risk markers in androgen-deficient women: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2014; 99:E1287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           True CA, Takahashi DL, Burns SE, et al. Chronic combined hyperandrogenemia and western-style diet in young female rhesus macaques causes greater metabolic impairments compared to either treatment alone. Hum Reprod 2017; 32:1880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bishop CV, Mishler EC, Takahashi DL, et al. Chronic hyperandrogenemia in the presence and absence of a western-style diet impairs ovarian and uterine structure/function in young adult rhesus monkeys. Hum Reprod 2018; 33:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corbould A. Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome? Diabetes Metab Res Rev 2008; 24:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eagleson CA, Gingrich MB, Pastor CL, et al. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000; 85:4047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blank SK, McCartney CR, Chhabra S, et al. Modulation of gonadotropin-releasing hormone pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls--implications for regulation of pubertal maturation. J Clin Endocrinol Metab 2009; 94:2360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumesic DA, Akopians AL, Madrigal VK, et al. Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage in Normal Weight Polycystic Ovary Syndrome Women. J Clin Endocrinol Metab 2016; 101:4178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corbould A, Dunaif A. The adipose cell lineage is not intrinsically insulin resistant in polycystic ovary syndrome. Metabolism 2007; 56:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahn CR. Knockout mice challenge our concepts of glucose homeostasis and the pathogenesis of diabetes. Exp Diabesity Res 2003; 4:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell 2014; 156:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varlamov O, Bishop CV, Handu M, et al. Combined androgen excess and Western-style diet accelerates adipose tissue dysfunction in young adult, female nonhuman primates. Hum Reprod 2017; 32:1892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ek I, Arner P, Rydén M, et al. A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. Diabetes 2002; 51:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arner P. Effects of testosterone on fat cell lipolysis. Species differences and possible role in polycystic ovarian syndrome. Biochimie 2005; 87:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Semple RK. EJE PRIZE 2015: How does insulin resistance arise, and how does it cause disease? Human genetic lessons. Eur J Endocrinol 2016; 174:R209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carmina E. Obesity, adipokines and metabolic syndrome in polycystic ovary syndrome. Front Horm Res 2013; 40:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cipolletta D. Adipose tissue-resident regulatory T cells: phenotypic specialization, functions and therapeutic potential. Immunology 2014; 142:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González F. Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role in the Development of Metabolic Aberration and Ovarian Dysfunction. Semin Reprod Med 2015; 33:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González F, Considine RV, Abdelhadi OA, Acton AJ. Saturated Fat Ingestion Promotes Lipopolysaccharide-Mediated Inflammation and Insulin Resistance in Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2019; 104:934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González F, Considine RV, Abdelhadi OA, Acton AJ. Inflammation Triggered by Saturated Fat Ingestion Is Linked to Insulin Resistance and Hyperandrogenism in Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2020; 105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banaszewska B, Siakowska M, Chudzicka-Strugala I, et al. Elevation of markers of endotoxemia in women with polycystic ovary syndrome. Hum Reprod 2020; 35:2303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jobira B, Frank DN, Pyle L, et al. Obese Adolescents With PCOS Have Altered Biodiversity and Relative Abundance in Gastrointestinal Microbiota. J Clin Endocrinol Metab 2020; 105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizk MG, Thackray VG. Intersection of Polycystic Ovary Syndrome and the Gut Microbiome. J Endocr Soc 2021; 5:bvaa177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliveira FR, Mamede M, Bizzi MF, et al. Brown adipose tissue activity is reduced in women with polycystic ovary syndrome. Eur J Endocrinol 2019; 181:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shorakae S, Jona E, de Courten B, et al. Brown adipose tissue thermogenesis in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2019; 90:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hussain MF, Roesler A, Kazak L. Regulation of adipocyte thermogenesis: mechanisms controlling obesity. FEBS J 2020; 287:3370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quinkler M, Sinha B, Tomlinson JW, et al. Androgen generation in adipose tissue in women with simple obesity--a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5. J Endocrinol 2004; 183:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Reilly MW, House PJ, Tomlinson JW. Understanding androgen action in adipose tissue. J Steroid Biochem Mol Biol 2014; 143:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bulun SE, Chen D, Moy I, et al. Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab 2012; 23:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenfield RL, Bordini B. Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity. Brain Res 2010; 1364:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srouji SS, Pagán YL, D'Amato F, et al. Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome. J Clin Endocrinol Metab 2007; 92:1347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maas KH, Chuan S, Harrison E, et al. Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome. Fertil Steril 2016; 106:1252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unlu E, Unlu BS, Yildiz Y, et al. Adrenal gland volume assessed by magnetic resonance imaging in women with polycystic ovary syndrome. Diagn Interv Imaging 2016; 97:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swart AC, du Toit T, Gourgari E, et al. Steroid hormone analysis of adolescents and young women with polycystic ovarian syndrome and adrenocortical dysfunction using UPC2-MS/MS. Pediatr Res 2021; 89:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenfield RL. Evidence that idiopathic functional adrenal hyperandrogenism is caused by dysregulation of adrenal steroidogenesis and that hyperinsulinemia may be involved. J Clin Endocrinol Metab 1996; 81:878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaltsas GA, Androulakis II, Tziveriotis K, et al. Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly. Clin Endocrinol (Oxf) 2007; 67:917.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5799 Version 29.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27459230" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22143833" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Uncertainty remains in women with PCOS regarding the increased incidence of cardiovascular disease later in life, despite the indisputable presence of multiple cardiovascular risk factors at a young age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27074389" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Body-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34061968" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Women With Polycystic Ovary Syndrome Have an Increased Risk of Major Cardiovascular Events: a Population Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34803918" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The Genetic Association of Polycystic Ovary Syndrome and the Risk of Endometrial Cancer: A Mendelian Randomization Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35436960" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34669940" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Causes and Consequences of Polycystic Ovary Syndrome: Insights From Mendelian Randomization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11344202" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34969092" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Evidence From Men for Ovary-independent Effects of Genetic Risk Factors for Polycystic Ovary Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28333238" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clustering of PCOS-like traits in naturally hyperandrogenic female rhesus monkeys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16219714" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Heritability of polycystic ovary syndrome in a Dutch twin-family study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32363240" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Endocrine-Metabolic Dysfunction in Polycystic Ovary Syndrome: an Evolutionary Perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35012577" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Polycystic ovary syndrome as a plausible evolutionary outcome of metabolic adaptation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16449341" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11163816" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16632599" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19223518" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19567527" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31792459" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Prenatal androgen exposure and transgenerational susceptibility to polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8334753" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Evidence for a single gene effect causing polycystic ovaries and male pattern baldness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9920059" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18559912" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Ovarian morphology is a marker of heritable biochemical traits in sisters with polycystic ovaries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21752884" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Circulating testosterone and SHBG concentrations are heritable in women: the Framingham Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9843997" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25336708" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Evidence for gonadotrophin secretory and steroidogenic abnormalities in brothers of women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28912339" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Reproductive and metabolic features during puberty in sons of women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21908468" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27846231" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Analysis of VEGFA Variants and Changes in VEGF Levels Underscores the Contribution of VEGF to Polycystic Ovary Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27846214" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Proteomic Profiling for Identification of Novel Biomarkers Differentially Expressed in Human Ovaries from Polycystic Ovary Syndrome Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27035648" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Transcription factor‑microRNA synergistic regulatory network revealing the mechanism of polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26935780" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Point mutation in mitochondrial tRNA gene is associated with polycystic ovary syndrome and insulin resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28602111" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Genetics of polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30786001" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Functional Genetic Variation in the Anti-Müllerian Hormone Pathway in Women With Polycystic Ovary Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34118374" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Prevalence of Polycystic Ovary Syndrome in Patients With McCune Albright Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30566500" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31184707" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : miRNA Profiling Reveals miRNA-130b-3p Mediates DENND1A Variant 2 Expression and Androgen Biosynthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22180642" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21151128" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29325736" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Differential association of DENND1A genetic variants with polycystic ovary syndrome in Tunisian but not Bahraini Arab women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27297658" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Alternative splicing of DENND1A, a PCOS candidate gene, generates variant 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32268539" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Human DENND1A.V2 Drives Cyp17a1 Expression and Androgen Production in Mouse Ovaries and Adrenals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31038695" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Family-Based Quantitative Trait Meta-Analysis Implicates Rare Noncoding Variants in DENND1A in Polycystic Ovary Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32574161" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32019676" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : MiR-3940-5p promotes granulosa cell proliferation through targeting KCNA5 in polycystic ovarian syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32226248" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Evaluation of Serum miRNA-24, miRNA-29a and miRNA-502-3p Expression in PCOS Subjects: Correlation with Biochemical Parameters Related to PCOS and Insulin Resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32304754" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Decreased microRNA-125b-5p disrupts follicle steroidogenesis through targeting PAK3/ERK1/2 signalling in mouse preantral follicles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31723719" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Colocalization of Polycystic Ovary Syndrome Candidate Gene Products in Theca Cells Suggests Novel Signaling Pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34403358" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Molecular diagnosis of polycystic ovary syndrome in obese and non-obese women by targeted plasma miRNA profiling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31848372" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Synergistic Effects of Hyperandrogenemia and Obesogenic Western-style Diet on Transcription and DNA Methylation in Visceral Adipose Tissue of Nonhuman Primates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25825716" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Alternative splicing of the androgen receptor in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33262817" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Androgen receptor gene mutations in 258 Han Chinese patients with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30959484" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : DNA methylation in the pathogenesis of polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32283997" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : DNA methylation in promoter regions of genes involved in the reproductive and metabolic function of children born to women with PCOS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1464643" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28566439" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26643539" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Maternal polycystic ovary syndrome and the risk of autism spectrum disorders in the offspring: a population-based nationwide study in Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28789693" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A novel method to demonstrate that pregnant women with polycystic ovary syndrome hyper-expose their fetus to androgens as a possible stepping stone for the developmental theory of PCOS. A pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32310267" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33764313" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Androgen-induced epigenetic modulations in the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32387276" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Does a compromised placenta contribute to transgenerational transmission of metabolic dysfunction in polycystic ovary syndrome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15744016" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Neuroendocrine consequences of prenatal androgen exposure in the female rat: absence of luteinizing hormone surges, suppression of progesterone receptor gene expression, and acceleration of the gonadotropin-releasing hormone pulse generator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25550522" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Enhancement of a robust arcuate GABAergic input to gonadotropin-releasing hormone neurons in a model of polycystic ovarian syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29618656" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Ontogeny and reversal of brain circuit abnormalities in a preclinical model of PCOS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28320971" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34346492" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Prenatal Androgen Exposure Alters KNDy Neurons and Their Afferent Network in a Model of Polycystic Ovarian Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34529765" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Reproductive Deficits Induced by Prenatal Antimüllerian Hormone Exposure Require Androgen Receptor in Kisspeptin Cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29760445" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30630591" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Circulating antimüllerian hormone and steroid hormone levels remain high in pregnant women with polycystic ovary syndrome at term.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33539777" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Polycystic ovary syndrome is transmitted via a transgenerational epigenetic process.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3086881" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : The arachidonic acid cascade is involved in the masculinizing action of testosterone on embryonic external genitalia in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19846715" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Prostaglandin E2-induced masculinization of brain and behavior requires protein kinase A, AMPA/kainate, and metabotropic glutamate receptor signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25821913" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Brain feminization requires active repression of masculinization via DNA methylation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9768664" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34081616" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Clinical and biochemical signs of polycystic ovary syndrome in young women born preterm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25637475" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Insulin resistance and hyperandrogenism have no substantive association with birth weight in adolescents with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25790331" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Birth weight and polycystic ovary syndrome in adult life: is there a causal link?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32344436" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Associations of childhood adiposity with menstrual irregularity and polycystic ovary syndrome in adulthood: the Childhood Determinants of Adult Health Study and the Bogalusa Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8222298" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33602559" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35048126" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7962325" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33788946" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Normal and Premature Adrenarche.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34060603" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : PCOS Features and Steroid Profiles Among Young Adult Women with a History of Premature Adrenarche.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32074632" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Unfavorable Hormonal and Psychologic Profile in Adult Women with a History of Premature Adrenarche and Pubarche, Compared to Women with Polycystic Ovary Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27342273" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Prenatal Exposure to Endocrine Disruptors: A Developmental Etiology for Polycystic Ovary Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27559705" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Polycystic ovary syndrome and environmental toxins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19240152" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Characterization of functionally typical and atypical types of polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7671850" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20501640" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31599939" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Inflammatory Stimuli Trigger Increased Androgen Production and Shifts in Gene Expression in Theca-Interstitial Cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31332392" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25202833" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Intraovarian control of early folliculogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9637695" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Androgens stimulate early stages of follicular growth in the primate ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9814480" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10579345" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2670645" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29220530" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Impaired Lipolysis, Diminished Fat Oxidation, and Metabolic Inflexibility in Obese Girls With Polycystic Ovary Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34752415" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Non-cell autonomous mechanisms control mitochondrial gene dysregulation in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29264544" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Insulin Resistance, Hyperinsulinemia, and Mitochondria Dysfunction in Nonobese Girls With Polycystic Ovarian Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19366843" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : KLF15 Is a transcriptional regulator of the human 17beta-hydroxysteroid dehydrogenase type 5 gene. A potential link between regulation of testosterone production and fat stores in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26903641" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Brown adipose tissue transplantation ameliorates polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17332526" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17986639" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24712568" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Testosterone dose-response relationships with cardiovascular risk markers in androgen-deficient women: a randomized, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28854721" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Chronic combined hyperandrogenemia and western-style diet in young female rhesus macaques causes greater metabolic impairments compared to either treatment alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29190387" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Chronic hyperandrogenemia in the presence and absence of a western-style diet impairs ovarian and uterine structure/function in young adult rhesus monkeys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18615851" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11095431" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19351732" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Modulation of gonadotropin-releasing hormone pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls--implications for regulation of pubertal maturation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27571186" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage in Normal Weight Polycystic Ovary Syndrome Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17445549" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : The adipose cell lineage is not intrinsically insulin resistant in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15061645" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Knockout mice challenge our concepts of glucose homeostasis and the pathogenesis of diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24439368" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : What we talk about when we talk about fat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28854720" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Combined androgen excess and Western-style diet accelerates adipose tissue dysfunction in young adult, female nonhuman primates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11812759" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15733735" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Effects of testosterone on fat cell lipolysis. Species differences and possible role in polycystic ovarian syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26865583" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : EJE PRIZE 2015: How does insulin resistance arise, and how does it cause disease? Human genetic lessons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24002404" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Obesity, adipokines and metabolic syndrome in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24484282" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Adipose tissue-resident regulatory T cells: phenotypic specialization, functions and therapeutic potential.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26132932" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role in the Development of Metabolic Aberration and Ovarian Dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30590569" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Saturated Fat Ingestion Promotes Lipopolysaccharide-Mediated Inflammation and Insulin Resistance in Polycystic Ovary Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32140727" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Inflammation Triggered by Saturated Fat Ingestion Is Linked to Insulin Resistance and Hyperandrogenism in Polycystic Ovary Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32869098" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Elevation of markers of endotoxemia in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31970418" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Obese Adolescents With PCOS Have Altered Biodiversity and Relative Abundance in Gastrointestinal Microbiota.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33381671" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Intersection of Polycystic Ovary Syndrome and the Gut Microbiome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31491743" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Brown adipose tissue activity is reduced in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30548504" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Brown adipose tissue thermogenesis in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32301220" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Regulation of adipocyte thermogenesis: mechanisms controlling obesity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15531721" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Androgen generation in adipose tissue in women with simple obesity--a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24787657" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Understanding androgen action in adipose tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22169755" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Aromatase, breast cancer and obesity: a complex interaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20816944" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17264175" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27473350" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26361992" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Adrenal gland volume assessed by magnetic resonance imaging in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32247282" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Steroid hormone analysis of adolescents and young women with polycystic ovarian syndrome and adrenocortical dysfunction using UPC2-MS/MS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8772543" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Evidence that idiopathic functional adrenal hyperandrogenism is caused by dysregulation of adrenal steroidogenesis and that hyperinsulinemia may be involved.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17651451" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
